Drugs / Cilofexor
Trials 12 · a red edge is where a trial was stopped
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-11-09 | Gilead Sciences | Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018 gilead.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cilofexor | “the farnesoid X receptor agonist cilofexor (CILO) and the acetyl-CoA carboxylase inhibitor firsocostat (FIR) improved liver histology and biomarkers in NASH with advanced fibrosis” PMID 34999207 ↗ Jan 202210“BACKGROUND AND AIMS: We evaluated the safety and efficacy of cilofexor (formerly GS-9674), a small-molecule nonsteroidal agonist of farnesoid X receptor” PMID 32115759 ↗ Jul 2020 “Cilofexor (CILO)” NCT03449446 ↗ |
| Known as | CILO | “the farnesoid X receptor agonist cilofexor (CILO) and the acetyl-CoA carboxylase inhibitor firsocostat (FIR) improved liver histology and biomarkers in NASH with advanced fibrosis” PMID 34999207 ↗ Jan 2022 |
| Known as | GS-9674 | “A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function” NCT02808312 ↗ |
| Known as | Px-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01999101 ↗ |
| Action | Activate | “Farnesoid X Receptor (FXR) Agonist” NCT01999101 ↗1“Bile acid receptor FXR agonist” CHEMBL4297613 ↗ |
| Modality | Small molecule | “a small-molecule nonsteroidal agonist of farnesoid X receptor” PMID 32115759 ↗ Jul 2020 |
| Route | Oral | “Administered orally once daily” NCT02781584 ↗ |
| Target | NR1H4 | “Bile acid receptor FXR agonist” CHEMBL4297613 ↗ |